Post-chemotherapy alopecia: what the dermatologist needs to know

Area of Science:

• Oncology
• Dermatology
• Trichology

Background:

• Chemotherapy-induced alopecia (CIA) is a common and distressing side effect affecting an estimated 65% of patients undergoing chemotherapy.
• Hair loss is considered the most traumatic aspect of cancer therapy by 47% of patients.

Purpose of the Study:

• To highlight the prevalence and impact of chemotherapy-induced alopecia.
• To emphasize the importance of anticipating and managing CIA.
• To discuss the role of dermatologists in evaluating and treating post-chemotherapy hair loss, including permanent cases.

Main Methods:

• Review of existing literature and clinical observations regarding chemotherapy-induced alopecia.
• Discussion of diagnostic tools such as trichoscopy for pre-treatment evaluation.
• Analysis of the increasing reports of permanent chemotherapy-induced alopecia.

Main Results:

• Chemotherapy-induced alopecia is a frequent occurrence, with incidence varying by chemotherapy regimen.
• A significant portion of cancer patients find hair loss to be the most traumatic aspect of their treatment.
• There is a growing recognition of permanent chemotherapy-induced alopecia cases requiring specific interventions.

Conclusions:

• Healthcare providers should be aware of treatments that can minimize CIA.
• Pre-chemotherapy evaluation, potentially including trichoscopy, is recommended.
• Dermatological evaluation and treatment are increasingly necessary for patients experiencing persistent or permanent hair loss post-chemotherapy.